Eli Lilly and Novo Nordisk agree to lower U.S. drug prices

For investors, the issue is not just lower list prices but the broader template Trump is building for future drug negotiations. The White House said Medicare pricing for Ozempic, Wegovy, Mounjaro and Zepbound will be set at $245, with a $50 monthly co-pay for beneficiaries, and that state Medicaid programs will get access at those price points for the first time.

That raises the stakes for the entire pharmaceutical sector, especially makers of high-demand specialty medicines that have relied on U.S. pricing power to offset discounts abroad. The administration says the companies will also extend MFN pricing to future drugs and repatriate more revenue from overseas sales, signaling a longer-running squeeze on margins if the policy spreads beyond Lilly and Novo.

The deal also carries industrial policy implications. Novo Nordisk said it will add $10 billion in U.S. investment, including domestic production of a Wegovy tablet, while Eli Lilly said it plans at least $27 billion in new U.S. manufacturing investment, underscoring how price concessions are being paired with onshore capacity commitments.

The market backdrop suggests investors are watching the policy as part of a broader shift in Washington’s bargaining power. The S&P 500 has been resilient, with the SPY ETF recently near 770, but healthcare names remain exposed to political pricing pressure, and the drugmakers’ commitment to MFN terms could influence valuations across obesity, diabetes and insulin franchises.

Trump has now announced five drug agreements since Sept. 30, making this a multi-company campaign rather than a one-off headline. The next catalyst is whether the administration can translate these bilateral deals into a wider pricing framework without triggering a broader challenge to pharmaceutical profits or future R&D spending.